Palleon Pharmaceuticals shares findings from the Phase 1/2 GLIMMER-01 study on E-602 combined with Cemiplimab for solid tumor patients at the SITC Annual Meeting.

NextCure presents preclinical findings for LNCB74 and new clinical biomarker results for the NC410 combination at the Society for Immunotherapy of Cancer Annual Meeting.

Dupixent has been authorized in the EU as the first and sole treatment for young children suffering from eosinophilic esophagitis.

Hanmi Introduces New Obesity Treatment ‘HM17321’: A Breakthrough in Addressing Muscle Loss Linked to GLP-1.

Minghui Pharmaceutical Reports Positive Early Findings from Phase I Trial of MHB039A, a New Bispecific Antibody Targeting PD-1 and VEGF.

Arcus Biosciences reports that the combination of Domvanalimab and Zimberelimab enhanced overall survival in the ARC-10 trial involving patients with high PD-L1 NSCLC.

OSE Immunotherapeutics reports noteworthy and statistically significant findings from the Phase 2 trial of Lusvertikimab, an anti-IL7R monoclonal antibody.

European Medicines Agency Approves Marketing Authorization Application for AVT05, a Biosimilar to Simponi® (golimumab).

Korro Bio has announced that it has submitted an application to the Bellberry HREC for a Phase 1/2 clinical trial of KRRO-110 targeting AATD.

HuidaGene Therapeutics Secures FDA Approval for HG202, the First CRISPR/Cas13 RNA-Editing Treatment for Macular Degeneration.

Cytoki Pharma has dosed the first patient in its Phase 2 trial for CK-0045, targeting obesity and Type 2 diabetes.

Viking Therapeutics has announced that new clinical findings from its VK2735 obesity initiative were featured in two poster sessions at ObesityWeek® 2024.